Exhibit 99.1 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights ● Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedback ● HB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) ● Received FDA clearance for Investigational New Drug (IND) applica ...